

1 **No Correlation of Structural Anterior-Segment OCT Biomarkers with Bleb**
2 **Vessel Density and Surgical Success after Preserflo Microshunt Implantation**

3

4 Martin Kallab¹, Sarah Hinterberger¹, Sophie Schneider¹, Olivia Murauer¹, Anna-
5 Sophie Reisinger¹, Susanne Strohmaier², Alex S. Huang³, Matthias Bolz¹, Clemens
6 A. Strohmaier¹

7

8 ¹ Department of Ophthalmology and Optometry, Kepler University Hospital,
9 Johannes Kepler University, Linz, Austria

10 ² Department of Epidemiology, Center for Public Health, Medical University of
11 Vienna, Vienna, Austria

12 ³ Hamilton Glaucoma Center, The Viterbi Family Department of Ophthalmology,
13 Shiley Eye Institute, University of California, San Diego, CA, USA

14

15 Correspondence to:

16 Clemens Strohmaier, MD, PhD

17 Department of Ophthalmology and Optometry

18 Kepler University Hospital Linz

19 Krankenhausstraße 9

20 4020 Linz

21 Phone No.: +43 5 768083-1050 // Fax.: +43 5 768083-1822

22 E-mail Address: clemens.strohmaier@kepleruniklinikum.at

23

24 Funding: This study was funded by NIH grant R01EY030501 (ASH) and an
25 unrestricted grant from Santen SA. Santen SA was not involved in study design and
26 conduct, data analysis and interpretation or manuscript production.

27 **Précis**

28 Bleb wall thickness and total bleb height 1, 2 and 4 weeks after Preserflo Microshunt
29 implantation do not correlate with bleb vessel density and necessity of future surgical
30 revision up to 12 months after surgery.

31

32 **Abstract**

33 Purpose

34 To evaluate anterior segment optical coherence tomography (AS-OCT) parameters
35 of bleb wall thickness (BWT) and total bleb height (TBH) in the early postoperative
36 phase after Preserflo Microshunt (PM) implantation for their correlation to (a) surgical
37 revision and (b) AS-OCT angiography (AS-OCTA) derived bleb vessel density (BVD).

38

39 Methods

40 A total of 23 patients with pharmacologically uncontrolled open angle glaucoma were
41 studied. Post-operatively (at 1, 2, and 4 weeks and 2, 3, 6, 9, and 12 months) AS-
42 OCT measurements of BWT/TBH and AS-OCTA measurements of BVD were
43 acquired. Surgical revisions (needling or open revision) were recorded. Correlations
44 of BWT and TBH to (a) need for surgical revision and to (b) BVD were assessed.

45

46 Results

47 In 10 of 23 patients, surgical revisions were performed 4 to 48 weeks after PM
48 implantation. At 1, 2, and 4 weeks after surgery neither BWT nor TBH were
49 significantly associated with future surgical revisions (BWT/TBH p-values: 1W
50 0.217/0.878, 2W 0.670/0.528, 4W 0.171/0.430). No correlations between BWT or
51 TBH and BVD were found for any evaluated timepoint (1W, 2W, 4W).

52

53 Conclusions

54 Structural AS-OCT parameters were not predictive of the need for surgical revision
55 after PM implantation. Consistent with this finding, these parameters were also not
56 correlated with AS-OCTA derived BVD, which was shown to be a good biomarker for
57 failure in a previous analysis. The discrepancy to similar studies after trabeculectomy
58 may be due to bleb drainage differences between TE and PM. BVD seems to be a
59 better predictor of surgical revision after PM implantation than BWT/TBH.

60

61 Key words: open angle glaucoma, Preserflo Microshunt, filtration surgery, bleb
62 failure, anterior segment optical coherence tomography, anterior segment optical
63 coherence tomography angiography

64 **Introduction**

65 Lowering intraocular pressure (IOP) is still the mainstay of glaucoma treatment.

66 Surgical options to lower IOP have seen numerous advancements towards a more
67 standardized and probably safer approach to filtration surgery. Still, a considerable
68 number of patients need secondary interventions (1) and therefore an intensified
69 follow-up regime is required for optimal patient care (2).

70 Filtration surgeries aim at generating an aqueous humor bypass from the anterior
71 chamber to the subconjunctival/subtenon space either by creating a surgical scleral
72 flap (trabeculectomy (TE)) or through implant-assisted procedures such as Xen gel
73 (XG) (3, 4) or more recently Preserflo Microshunt (PM) (5, 6). While TE consistently
74 shows greater IOP lowering efficacy than PM implantation, PM is still associated with
75 marked IOP reduction that is close to TE and demonstrates a favorable peri- and
76 postoperative risk profile.(7-9) Therefore, PM is increasingly deployed as a first-line
77 glaucoma surgery as opposed to traditional TE.(7-9)

78 Filtration surgeries in general depend on proper filtration bleb (FB) function and,
79 therefore, FB evaluation, either by clinical observation or by anterior segment
80 imaging, plays a central role in postoperative patient management. The value of
81 clinical bleb grading scales, e.g. the Moorfields Bleb Grading System (MBGS)(10)
82 and Indiana Bleb Appearance Grading Scale (IBAGS)(11), is, however, impaired by
83 partly subjective grading algorithms(12, 13). They also lack detailed evaluation of
84 internal bleb structure and dimensions. To overcome these limitations, anterior
85 segment optical-coherence tomography (AS-OCT) has been utilized to develop
86 objective biomarkers for bleb function.(14) Nowadays, bleb wall thickness (BWT) and
87 total bleb height (TBH) are among the most frequently studied quantitative AS-OCT-
88 based structural bleb parameters and have been repeatedly shown to correlate well

89 with bleb function after TE.(15-22) Results looking at the same endpoints after PM
90 implantation have been equivocal.(23-25)

91 Moreover, while existing cross-sectional data on correlation between concomitantly
92 recorded AS-OCT parameters and IOP undoubtedly help to extend our knowledge on
93 pathophysiological processes linked to bleb failure comprising vascularization,
94 fibrosis and bleb encapsulation, their utility in clinical routine care may, however, be
95 limited. From a clinical perspective, early biomarkers informing the clinician about
96 future bleb failure risk are needed to allow a personalized approach to glaucoma
97 patient care. For the above-mentioned quantitative AS-OCT based bleb parameters,
98 information on their predictive value is, however, scarce after TE (15, 16) and not
99 available after PM implantation. As we could recently identify AS-OCT angiography
100 (AS-OCTA) measured bleb vessel density (BVD) two and four weeks after surgery as
101 a predictor for surgical revision up to one year after PM primary surgery (26), we set
102 out to investigate this relationship for structural AS-OCT bleb parameters as well.

103 Therefore, the aim of the current analysis was to evaluate structural AS-OCT bleb
104 parameters, BWT and TBH, in the early postoperative phase concerning their
105 predictive value for surgical revision after PM implantation in a longitudinal study
106 cohort and to correlate those parameters with AS-OCTA derived bleb vascularity
107 information.

108 **Methods**

109 Study design and patient selection

110 The protocol of this single-center study (Department of Ophthalmology and
111 Optometry, Kepler University Hospital, Linz, Austria) was approved by the Ethics
112 Committee of the Johannes Kepler University (EC-No.: B-142-17). Written informed
113 consent was obtained from every patient before study inclusion and the tenets of the
114 Declaration of Helsinki were followed during all study-related procedures.

115

116 Inclusion criteria included glaucoma type (primary open angle glaucoma,
117 pseudoexfoliation glaucoma, or pigment dispersion glaucoma) and indication for PM
118 implantation (maximal tolerated IOP-reducing medical therapy AND uncontrolled IOP
119 > 21 mmHg and/or visual field (VF) progression as tested using the 30-2 SITA fast
120 algorithm of Humphrey Field Analyzer II 750 ((Carl Zeiss Meditec Inc., Dublin, CA,
121 USA) and/or progressive retinal nerve fiber layer thickness reduction as measured
122 using Spectralis OCT (Heidelberg Engineering, Heidelberg, Germany)). Exclusion
123 criteria included, angle closure glaucoma and previous filtration surgery.

124

125 Preserflo Microshunt: medical device and implantation surgery

126 Descriptions of in-depth surgical technique specifications of the PM medical device
127 (Santen Pharmaceutical, Osaka, Japan) have been published elsewhere.(5, 6)
128 Briefly, the PM glaucoma drainage device is made from poly(styrene-block-
129 isobutylene-block-styrene) (SIBS), a highly biocompatible and bioinert material, and
130 has following basic dimensions: length: 8.5mm, outer diameter: 350 µm, inner
131 diameter: 70 µm. In the European Union the PM is CE-marked and approved for use
132 as glaucoma drainage device, FDA approval is pending.

133 In this study, standard Mitomycin C (MMC) augmented PM implantation was
134 performed in the supero-temporal or supero-nasal quadrant under subtenon or
135 general anesthesia. MMC-soaked sponges (0.2 mg/ml) were applied for 3 minutes
136 after dissection of conjunctiva before the scleral pocket and tunnel to the anterior
137 chamber were created. Then, the PM was placed in the tunnel with its fins inside the
138 scleral pocket. Finally, flow through the implant was checked by balanced saline
139 solution injection, and conjunctival sutures were placed to close all wounds.

140

141 Postoperative treatment and examinations

142 Preservative-free antibiotic (Ofloxacin, 1 week) and steroid (Dexamethasone, tapered
143 over 12 weeks) drops were prescribed according to a standardized protocol. One,
144 two and four week(s), as well as two, three, six, nine and twelve months after surgery
145 slit-lamp examinations, IOP measurements, structural AS-OCT measurements
146 (Casia 2 Cornea/Anterior Segment OCT, Tomey Corporation, Nagoya, Japan) and
147 AS-OCTA measurements (PLEX Elite 9000; Carl Zeiss Meditec, Dublin, CA, USA)
148 were performed. Moreover, necessity and number of IOP lowering medications
149 (MEDs) as well as surgical revisions (needling or open revision) were recorded.
150 Experienced clinicians (S.SCH, A-S.R., CA.S.) offered a surgical revision if
151 postoperative IOP exceeded the preoperatively defined target pressure and no bleb
152 or a scared bleb was clinically visible. Depending on fulfilment of the endpoint
153 “surgical revision”, which included either needling or open revision, patients were
154 allocated to the outcome groups “surgical revision” or “no surgical revision”.

155

156 AS-OCT scan acquisition and image analysis

157 All AS-OCT images were acquired using the Casia2 AS-OCT with on-board software.
158 Operators instructed the patients to look down to expose the FB in the superior-nasal

159 or -temporal quadrant. Upon visualization of the FB and PM in the real-time preview
160 OCT-image, an AS-OCT volume was acquired using the standard settings of the
161 “Bleb” imaging mode (volume size 12x12mm, number of B-scans: 256, number of A-
162 scans per B-scan: 400). To measure BWT and TBH, a B-scan was selected based
163 on visibility of following structures to ensure intra- and inter-individual comparability:
164 posterior PM tip, complete bleb wall above PM, and episcleral fluid. If more than one
165 scan fulfilled all criteria, the B-scan with the higher bleb was selected. If no episcleral
166 fluid was visible in any scan (i.e. not present in individual bleb), this criterion was
167 omitted.

168 All AS-OCTA images were acquired using the PLEX Elite 9000 OCTA in combination
169 with a 10dpt anterior segment add-on lens. Details of our AS-OCTA image
170 processing and BVD calculation approach were published previously.(26) In short,
171 AS-OCTA slabs with the PM scleral passage position marked in an overlay were
172 exported. Using Fiji ImageJ (27) motion artifacts were removed, before a circular
173 region of interest (400px diameter) centered around the scleral passage of the PM
174 was defined. Images were then binarized, and the BVD was calculated as the
175 proportion of white pixels.

176

177 Statistical analysis

178 If not differently indicated, all values were presented as means±standard deviation
179 (SD). Logistic regression modelling in combination with the likelihood-ratio test was
180 used to evaluate predictive value of independent variables (BWT or TBH) for the
181 dependent dichotomic variable (surgical revision and no surgical revision). Pearson
182 bivariate correlation was used to evaluate associations of structural AS-OCT
183 parameters (BWT and TBH) with AS-OCTA parameters (BVD). Prism 10 (GraphPad
184 Software, Boston, MA, USA) was used for statistical testing and graph production.

185 **Results**

186 Baseline characteristics

187 Twenty-three patients with OAG and preoperative IOP of 23.57 ± 7.75 mmHg received
188 PM implantation and were included in this study. In ten patients, needling or open
189 revision were performed during the follow up period of 1 year. Earliest surgical
190 revisions were performed after the 4 weeks' postoperative follow-up. Further baseline
191 characteristics in the whole cohort and the two outcome groups are summarized in
192 Table 1.

193

194 Descriptive statistics of postoperative IOP, BWT and TBH

195 Postoperative IOP one, two and four week(s), as well as two, three, six, nine and
196 twelve months after surgery were 8.30 ± 2.12 , 9.17 ± 2.33 , 11.70 ± 4.39 , 13.48 ± 5.83 ,
197 11.87 ± 4.49 , 12.30 ± 6.65 , 11.87 ± 3.11 and 13.05 ± 4.12 mmHg. Postoperative BWTs
198 and TBHs over time are summarized in Table 2 and Figure.

199

200 Association of BWT and TBH with future surgical revision

201 As earliest surgical revisions were performed after the 4 weeks' postoperative follow-
202 up, 1,2 and 4 weeks' BWT and TBH were evaluated. Upon logistic regression
203 modelling, both, BWT and TBH, 1, 2 and 4 weeks after surgery were not found to be
204 significantly associated with future surgical revisions (BWT/TBH likelihood-ratio test
205 p-values: 1W 0.2169/0.8776, 2W 0.6704/0.5281, 4W 0.1706/0.4298). Areas under
206 the receiver operating characteristics curves (AUROCs) were low for both
207 parameters at all evaluated timepoints (BWT/TBH AUROCSs 1W: 0.612/0.519, 2W:
208 0.539/0.581, 4W: 0.631/0.585).

209

210

211 Correlation between structural (BWT, TBH) and vascular (BVD) data

212 As we could recently show, that AS-OCTA measured BVDs 2 and 4 weeks after PM
213 implantation are predictive for future surgical revision (26), correlations between
214 structural parameters (BWT and TBH) and bleb vascularity (BVD) were evaluated.
215 No significant correlations could be found for any timepoint or parameter (Pearson r
216 between 0.339 and -0.170, $p > 0.05$ for all correlations). Detailed results are
217 summarized in Table 3.

218 **Discussion**

219 In this study we analyzed the predictive value of two quantitative, AS-OCT derived
220 bleb parameters (BWT and TBH) in the early postoperative phase for surgical
221 revision after PM implantation. Both, BWT and TBH, did not predict surgical revisions
222 after PM implantation and did not correlate with AS-OCTA-measured bleb vascularity
223 (BVD) at 1, 2 or 4 weeks after primary surgery. The latter analysis was performed
224 because we found BVD to be an early predictive marker for future surgical revision
225 up to one year after PM implantation in the same cohort.(26)

226

227 In an effort to find objective markers for bleb function AS-OCT has become an
228 increasingly popular tool both in clinical research and routine care.(14) Concerning
229 bleb evaluation after PM implantation, 3 studies have evaluated correlations of
230 quantitative bleb markers with IOP and obtained inconsistent results.(23-25) In 2022
231 Ibarz Barbera et. al found no correlations between IOP and horizontal or vertical
232 (TBH minus BWT) bleb dimensions in a longitudinal study with up to 3 months follow
233 up.(25) The same group later analyzed various bleb parameters in a cross-sectional
234 design 1 year after PM implantation and reported a significant correlation of TBH and
235 BWT with surgical success (defined by IOP between 6 and 17 mmHg and $\geq 20\%$
236 reduction without medication) in univariate analysis, which did not persist upon
237 multivariate analysis.(24) Finally, in a retrospective cross-sectional analysis, Gambini
238 et al. did not find associations between bleb dimensions and IOP 6 months after PM
239 implantation.(23)

240 The course of BWT and TBH in our cohort is, however, comparable to published
241 values by Ibarz Barbera et al. after PM implantation with a noticeable increase of
242 both parameters in the first 3-6 months, transitioning to a plateau-like phase in the
243 second half of the one year follow-up period.(24)

244 The available body of evidence for predictive AS-OCT biomarkers after TE is in
245 contrast to our results for PM. Narita et al. found TBH and BWT after 2 weeks to be
246 predictive for surgical success (defined by an IOP \leq 15 mmHg and $>$ 20% reduction
247 without surgical revision) up to one year after surgery.(16) Waibel et al. detected
248 higher BWT as early as one week and higher bleb cavity height (TBH minus BWT)
249 two weeks after TE in functioning blebs as compared to non-functioning blebs in a
250 follow-up period of three months.(15) These data are backed by further studies
251 showing correlations (at the same timepoints) between quantitative AS-OCT bleb
252 parameters and IOP (or IOP-based success endpoints) after TE.(17-22)

253 A possible reason for the discrepancy between TE and PM, could be differences in
254 bleb position and morphology as recently detected by Hasan et al. in an extensive
255 comparative study of functioning blebs after TE and PM implantation.(28) Compared
256 to TE blebs, PM blebs showed reduced conjunctival microcysts, a more consistent
257 Tenon appearance and a more posterior drainage (through posterior PM tip where
258 Tenon's capsule is thicker). Based on these findings the authors suggested bleb
259 drainage differences between the two surgical techniques.(28)

260 In this context it appears also notable that the vascular parameter BVD, which is
261 independent of bleb thickness, was recently found to be an early predictive marker
262 for surgical revision after PM implantation by our research group.(26) This result
263 agrees with AS-OCTA-based vascularity biomarkers after TE (29-31) which could be
264 indicative for a more procedure-independent validity of bleb vascularity biomarkers.

265

266 Studies correlating or combining, structural AS-OCT-based and vascular AS-OCTA-
267 based bleb parameters are rare and currently available for TE and XG implantation
268 but not for PM implantation. Yin et al. found a correlation between vessel area and
269 TBH 1 month after TE.(31) Hayek et al. analyzed preoperative conjunctival vessel

270 density and found an association with postoperative microcysts.(30) Six months after
271 XG implantation, Mastropasqua et al. detected a correlation of TBH and bleb wall
272 microcysts with vessel displacement area, a marker for flow voids.(32) In an effort to
273 combine structural and angiographic data Luo et al. designed an objective bleb
274 evaluation score in which information on vessel density, bleb height and microcysts
275 were included.(33)

276 To our knowledge the current study is the first to correlate AS-OCT-based structural
277 and AS-OCTA-based vascular bleb parameters after PM implantation. While these
278 correlations are all statistically insignificant, this result does not come as a surprise
279 as BVD at two of the three presented timepoints (postoperative week two and four)
280 were recently shown to be an early predictor of surgical revision after PM
281 implantation (26) and BWT/TBH, as presented in this study, are not. Discrepancy of
282 BWT/TBH data between TE and PM implantation, as above extensively discussed,
283 might also explain diverging results between the study of Yin et al. and our
284 analysis.(31)

285

286 The present study has several strengths and limitations. Concomitant presentation
287 and correlation of AS-OCT- and AS-OCTA-based parameters, the prospective study
288 design and the concise, clinically relevant endpoint definition are strengths of this
289 study. While the two earlier points have already been thoroughly discussed, the latter
290 shall also be briefly outlined. We deliberately refrained from including IOP to our
291 endpoint definition, which is commonly used in comparable studies. Instead, we
292 relied solely on the clinically relevant necessity for surgical revision, which is related
293 to both IOP and clinical bleb appearance. This was done to avoid misclassification as
294 bleb failure solely based on concepts such as threshold IOP or percent IOP reduction
295 as both may be arbitrary and definitely depend on baseline IOP.

296 An obvious limitation of this study is its rather small sample size, especially as we
297 present not significant, negative results and draw conclusions. The sample size in the
298 present study would, however, at least have allowed for the detection of an
299 association if the min/max values for either parameters modified this risk by 20%,
300 assuming a baseline surgical revision incidence of 30%. Furthermore, we consider
301 the type II error risk to be low due to following two circumstances: 1) AS-OCT studies
302 after TE with comparable sample sizes detected differences in bleb thickness
303 parameters.(15, 19) 2) We recently found BVD two and four weeks after PM
304 implantation to be a predictor for surgical revision in a study with comparable sample
305 size.(26)

306

307 In conclusion, structural AS-OCT-based bleb thickness parameters (BWT and TBH)
308 in the early postoperative phase, were not found to be predictive for surgical revision
309 after PM implantation and did not correlate with AS-OCTA-derived BVD. Discrepancy
310 to the value of quantitative AS-OCT parameters after TE and recently published AS-
311 OCTA-derived vascular parameters after PM implantation may be associated with
312 differences in bleb drainage between TE and PM. AS-OCTA-derived BVD seems to
313 be a better predictor of surgical revision after PM implantation than BWT/TBH.

314 **References**

- 315 1. Marolo P, Reibaldi M, Fallico M, Maugeri A, Barchitta M, Agodi A, et al.
316 Reintervention rate in glaucoma filtering surgery: A systematic review and meta-
317 analysis. *Eur J Ophthalmol.* 2022;32(5):2515-31.
- 318 2. Marquardt D, Lieb WE, Grehn F. Intensified postoperative care versus
319 conventional follow-up: a retrospective long-term analysis of 177 trabeculectomies.
320 *Graefes Arch Clin Exp Ophthalmol.* 2004;242(2):106-13.
- 321 3. Schlenker MB, Gulamhusein H, Conrad-Hengerer I, Somers A, Lenzhofer M,
322 Stalmans I, et al. Efficacy, Safety, and Risk Factors for Failure of Standalone Ab
323 Interno Gelatin Microstent Implantation versus Standalone Trabeculectomy.
324 *Ophthalmology.* 2017;124(11):1579-88.
- 325 4. Lewis RA. Ab interno approach to the subconjunctival space using a collagen
326 glaucoma stent. *J Cataract Refract Surg.* 2014;40(8):1301-6.
- 327 5. Pinchuk L, Riss I, Batlle JF, Kato YP, Martin JB, Arrieta E, et al. The use of
328 poly(styrene-block-isobutylene-block-styrene) as a microshunt to treat glaucoma.
329 *Regen Biomater.* 2016;3(2):137-42.
- 330 6. Pinchuk L, Riss I, Batlle JF, Kato YP, Martin JB, Arrieta E, et al. The
331 development of a micro-shunt made from poly(styrene-block-isobutylene-block-
332 styrene) to treat glaucoma. *J Biomed Mater Res B Appl Biomater.* 2017;105(1):211-
333 21.
- 334 7. Batlle JF, Fantes F, Riss I, Pinchuk L, Albuquerque R, Kato YP, et al. Three-
335 Year Follow-up of a Novel Aqueous Humor MicroShunt. *J Glaucoma.*
336 2016;25(2):e58-65.
- 337 8. Baker ND, Barnebey HS, Moster MR, Stiles MC, Vold SD, Khatana AK, et al.
338 Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma:

- 339 One-Year Results from a 2-Year Randomized, Multicenter Study. *Ophthalmology*.
340 2021;128(12):1710-21.
- 341 9. Beckers HJM, Aptel F, Webers CAB, Bluwol E, Martinez-de-la-Casa JM,
342 Garcia-Feijoo J, et al. Safety and Effectiveness of the PRESERFLO(R) MicroShunt in
343 Primary Open-Angle Glaucoma: Results from a 2-Year Multicenter Study.
344 *Ophthalmol Glaucoma*. 2022;5(2):195-209.
- 345 10. Wells AP, Crowston JG, Marks J, Kirwan JF, Smith G, Clarke JC, et al. A pilot
346 study of a system for grading of drainage blebs after glaucoma surgery. *J Glaucoma*.
347 2004;13(6):454-60.
- 348 11. Cantor LB, Mantravadi A, WuDunn D, Swamynathan K, Cortes A. Morphologic
349 classification of filtering blebs after glaucoma filtration surgery: the Indiana Bleb
350 Appearance Grading Scale. *J Glaucoma*. 2003;12(3):266-71.
- 351 12. Hoffmann EM, Herzog D, Wasielica-Poslednik J, Butsch C, Schuster AK. Bleb
352 grading by photographs versus bleb grading by slit-lamp examination. *Acta*
353 *Ophthalmol*. 2020;98(5):e607-e10.
- 354 13. Wells AP, Ashraff NN, Hall RC, Purdie G. Comparison of two clinical Bleb
355 grading systems. *Ophthalmology*. 2006;113(1):77-83.
- 356 14. Kudsieh B, Fernandez-Vigo JI, Canut Jordana MI, Vila-Arteaga J, Urcola JA,
357 Ruiz Moreno JM, et al. Updates on the utility of anterior segment optical coherence
358 tomography in the assessment of filtration blebs after glaucoma surgery. *Acta*
359 *Ophthalmol*. 2022;100(1):e29-e37.
- 360 15. Waibel S, Spoerl E, Furashova O, Pillunat LE, Pillunat KR. Bleb Morphology
361 After Mitomycin-C Augmented Trabeculectomy: Comparison Between Clinical
362 Evaluation and Anterior Segment Optical Coherence Tomography. *J Glaucoma*.
363 2019;28(5):447-51.

- 364 16. Narita A, Morizane Y, Miyake T, Seguchi J, Baba T, Shiraga F. Characteristics
365 of early filtering blebs that predict successful trabeculectomy identified via three-
366 dimensional anterior segment optical coherence tomography. *Br J Ophthalmol.*
367 2018;102(6):796-801.
- 368 17. Zantut F, Gracitelli CPB, Souza PH, Teixeira SH, Paranhos A, Jr.
369 Characteristics of the Filtering Bleb and the Agreement between Glaucoma Specialist
370 and Anterior Segment-Optical Coherence Tomography Assessment. *Ophthalmic*
371 *Res.* 2021;64(3):405-10.
- 372 18. Mastropasqua L, Brescia L, Oddone F, Sacchi M, Aloia R, Totta M, et al.
373 Conjunctival thickness as a predictive imaging biomarker for the glaucoma filtration
374 surgery outcome: An optical coherence tomography study. *Clin Exp Ophthalmol.*
375 2020;48(9):1192-200.
- 376 19. Kawana K, Kiuchi T, Yasuno Y, Oshika T. Evaluation of trabeculectomy blebs
377 using 3-dimensional cornea and anterior segment optical coherence tomography.
378 *Ophthalmology.* 2009;116(5):848-55.
- 379 20. Singh M, Chew PT, Friedman DS, Nolan WP, See JL, Smith SD, et al.
380 Imaging of trabeculectomy blebs using anterior segment optical coherence
381 tomography. *Ophthalmology.* 2007;114(1):47-53.
- 382 21. Tekin S, Seven E, Batur M, Ozer MD, Yasar T. Evaluation of Successful and
383 Failed Filtering Blebs after Trabeculectomy Using Anterior Segment Optical
384 Coherence Tomography. *J Curr Ophthalmol.* 2021;33(1):1-5.
- 385 22. Raj A, Bahadur H. Morphological analysis of functional filtering blebs with
386 anterior segment optical coherence tomography: A short-term prediction for success
387 of trabeculectomy. *Eur J Ophthalmol.* 2021;31(4):1978-85.
- 388 23. Gambini G, Carla MM, Giannuzzi F, Boselli F, Grieco G, Caporossi T, et al.
389 Anterior Segment-Optical Coherence Tomography Bleb Morphology Comparison in

- 390 Minimally Invasive Glaucoma Surgery: XEN Gel Stent vs. PreserFlo MicroShunt.
391 Diagnostics (Basel). 2022;12(5).
- 392 24. Ibarz Barbera M, Hernandez-Verdejo JL, Bragard J, Morales-Fernandez L,
393 Rodriguez-Carrillo L, Martinez Galdon F, et al. Bleb geometry and morphology after
394 Preserflo Microshunt surgery: Risk factors for surgical failure. PLoS One.
395 2023;18(6):e0286884.
- 396 25. Ibarz Barbera M, Morales Fernandez L, Tana Rivero P, Gomez de Liano R,
397 Teus MA. Anterior-segment optical coherence tomography of filtering blebs in the
398 early postoperative period of ab externo SIBS microshunt implantation with
399 mitomycin C: Morphological analysis and correlation with intraocular pressure
400 reduction. Acta Ophthalmol. 2022;100(1):e192-e203.
- 401 26. Schneider S, Kallab M, Murauer O, Reisinger AS, Strohmaier S, Huang AS, et
402 al. Bleb vessel density as a predictive factor for surgical revisions after Preserflo
403 Microshunt implantation. Acta Ophthalmol. 2024.
- 404 27. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et
405 al. Fiji: an open-source platform for biological-image analysis. Nat Methods.
406 2012;9(7):676-82.
- 407 28. Hasan SM, Theilig T, Meller D. Comparison of Bleb Morphology following
408 PRESERFLO((R)) MicroShunt and Trabeculectomy Using Anterior Segment OCT.
409 Diagnostics (Basel). 2023;13(21).
- 410 29. Seo JH, Lee Y, Shin JH, Kim YA, Park KH. Comparison of conjunctival
411 vascularity changes using optical coherence tomography angiography after
412 trabeculectomy and phacotrabeculectomy. Graefes Arch Clin Exp Ophthalmol.
413 2019;257(10):2239-55.

- 414 30. Hayek S, Labbe A, Brasnu E, Hamard P, Baudouin C. Optical Coherence
415 Tomography Angiography Evaluation of Conjunctival Vessels During Filtering
416 Surgery. *Transl Vis Sci Technol.* 2019;8(4):4.
- 417 31. Yin X, Cai Q, Song R, He X, Lu P. Relationship between filtering bleb
418 vascularization and surgical outcomes after trabeculectomy: an optical coherence
419 tomography angiography study. *Graefes Arch Clin Exp Ophthalmol.*
420 2018;256(12):2399-405.
- 421 32. Mastropasqua R, Brescia L, Di Antonio L, Guarini D, Giattini D, Zuppardi E, et
422 al. Angiographic biomarkers of filtering bleb function after XEN gel implantation for
423 glaucoma: an optical coherence tomography-angiography study. *Acta Ophthalmol.*
424 2020;98(6):e761-e7.
- 425 33. Luo M, Xiao H, Huang J, Jin L, Li Z, Tu S, et al. Multi-Quantitative Assessment
426 of AS-OCTA Complemented AS-OCT for Monitoring Filtering Bleb Function After
427 Trabeculectomy. *Transl Vis Sci Technol.* 2023;12(7):18.
- 428
- 429

430 **Figure/Table legends**

431 Table 1. Baseline characteristics

432 SR: surgical revision, OAG: open angle glaucoma, POAG: primary open angle

433 glaucoma, PDG: pigment dispersion glaucoma, PXG: pseudoexfoliation glaucoma,

434 MD: visual field mean deviation, dB: decibel, 1W: one week

435

436 Table 2. Tabulated time course of TBH and BWT values

437 TBH: total bleb height, BWT: bleb wall thickness

438

439 Figure. Time Course of bleb wall thickness (BWT) and total bleb height (TBH). TBH:

440 total bleb height, BWT: bleb wall thickness.

441

442 Table 3. Correlations between AS-OCT derived structural and AS-OCTA derived

443 vascular bleb parameters

444 BWT: bleb wall thickness, BVD: bleb vessel density, TBH: total bleb height

445

446 **Acknowledgements**

447 This study was funded by NIH grant R01EY030501 (ASH) and an unrestricted grant

448 from Santen SA. Santen SA was not involved in study design and conduct, data

449 analysis and interpretation or manuscript production.

450

451 **Financial disclosure**

452 CAS: Santen(Consultant, Research Support), Zeiss(Honorarium),

453 AbbVie(Consultant, Honorarium), Elios Vision (Consultant, Honorarium).

454 ASH: Allergan(C), Amydis(C), Celanese(C), Diagnosys(F), Equinox(C),

455 Glaukos(C,F), Heidelberg Engineering(F), QLARIS(C), Santen(C), Topcon(C).

Table 1. Baseline characteristics.

| | Whole cohort | SR | no SR |
|--|--------------|------------|-------------|
| N | 23 | 10 | 13 |
| Age (mean±SD) | 69.26±10.05 | 68.2±3.99 | 70.08±13.09 |
| Sex (f/m) | 13/10 | 5/5 | 8/5 |
| OAG type (POAG/PDG/PXG) | 17/1/5 | 9/0/1 | 8/1/4 |
| MD (dB, mean±SD) | -9.83±7.43 | -6.13±5.74 | -12.67±7.52 |
| IOP-preOP | 23.57±7.75 | 24.40±8.80 | 22.92±7.15 |
| MEDs-preOP (mean±SD) | 2.96±1.11 | 3.40±0.52 | 2.62±1.33 |
| IOP-postOP (1W) | 8.30±2.12 | 9.60±1.84 | 7.31±1.80 |
| Timepoint of SR (week, median, min-max) | - | 10, 4-48 | - |

| Table 2. Tabulated time course of TBH and BWT values. | | |
|---|-----------------------|-----------------------|
| Postoperative Timepoint | TBH [μm] | BWT [μm] |
| 1 week | 996 \pm 218 | 538 \pm 159 |
| 2 weeks | 1177 \pm 373 | 574 \pm 192 |
| 4 weeks | 1286 \pm 354 | 601 \pm 214 |
| 2 months | 1255 \pm 319 | 621 \pm 213 |
| 3 months | 1249 \pm 375 | 607 \pm 254 |
| 6 months | 1353 \pm 377 | 674 \pm 276 |
| 9 months | 1366 \pm 281 | 739 \pm 246 |
| 12 months | 1379 \pm 335 | 709 \pm 266 |




Table 3. Correlations between AS-OCT derived structural and AS-OCTA derived vascular bleb parameters.

| Variables | Pearson r | P Value |
|-----------------|-----------|---------|
| 1W BWT / 1W BVD | 0.339 | 0.1553 |
| 1W TBH / 1W BVD | 0.191 | 0.4330 |
| 2W BWT / 2W BVD | 0.119 | 0.6383 |
| 2W TBH / 2W BVD | -0.170 | 0.4990 |
| 4W BWT / 4W BVD | -0.081 | 0.7409 |
| 4W TBH / 4W BVD | -0.077 | 0.7527 |